An electrochemical biosensor for rapid detection of anti-dsDNA antibodies in absolute scale.

Pablo Fagúndez¹, Gustavo Brañas¹, Justo Laíz¹, Juan Pablo Tosar^{1,2*}

¹Nuclear Research Center, Faculty of Science. Universidad de la República. Montevideo 11400. Uruguay. ²Functional Genomics Unit. Institut Pasteur de Montevideo. Montevideo 11400. Uruguay. *Email: jptosar@cin.edu.uy

Keywords: Autoantibodies, Lupus, sensor, anti-dsDNA, point-of-care

Abstract

Autoimmune diseases are chronic inflammatory pathologies that are characterized by the presence of antibodies against own epitopes in serum (autoantibodies). Systemic lupus erythematosus (SLE) is a common autoimmune pathology, characterized by the presence of antinuclear antibodies (ANAs). These include anti-dsDNA (α -dsDNA) antibodies, which are widely used for diagnosis and disease monitoring. Their determination is carried out by traditional techniques such as Indirect Immunofluorescence (IFI) or Enzyme Linked Immunosorbent Assay (ELISA), which are time consuming, require qualified technicians, and are not compatible with decentralized analysis outside a laboratory facility. Here, we show a sandwich-format electrochemical biosensor-based method for α -dsDNA determination in a rapid and simple manner. Total assay time is only 30 minutes and the sensor is capable of detecting 16 ng (8 μ g / mL) of α -dsDNA antibodies. Using the current derived from the detection limit of the method as a cut-off, we could discriminate positive from negative serum samples with 90% sensitivity and 100% specificity. By using monoclonal antibodies for calibration curves, our results are presented in absolute scale (i.e., concentration instead of serum title) what will help to perform comparisons between methods and further improvements of this protocol. In an effort to render the sensor compatible with automation, we minimized manipulation steps without compromise of the analytical performance, even in complex samples such as serum.

Introduction

Autoimmune disorders are chronic inflammatory pathologies that affect over 5-8% of the world population¹. In these disorders, the immune response of the individual is directed against its own components causing tissue- or organ-specific damage, generating local or systemic responses. Common autoimmune diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, systemic sclerosis, type 1 diabetes, inflammatory bowel disease, and antiphospholipid syndrome. Diagnosis of these diseases is challenging for professionals, since their symptoms can vary between individuals and overlap with other rare pathologies^{2,3}. Moreover, their origin is still now difficult to understand because of the genetic and environmental factors involved in their appearance⁴. However, they share some common features, such as the presence of antibodies directed against own epitopes (autoantibodies).

SLE, considered as a model of autoimmune diseases, has been extremely studied and it has been reported more than a hundred autoantibodies which involve reactivity against nuclear, cytoplasmic and membrane components. The antinuclear antibodies (ANAs) are reactive against single and double strand DNA, histones, nucleosomes and chromatin, as well as other nuclear antigens (Ro, La and Sm ribonucleoproteins).⁵ Specific antibodies are associated with distinct clinical features. For example, the anti-dsDNA antibodies (α -dsDNA) are associated with the development of Lupus nephritis. Total ANAs, α -dsDNA and α -Sm antibodies are considered as the hallmarks of this pathology, and are included in the serological American College of Rheumatology (ACR) criteria for diagnosis.⁶⁻¹⁰ SLE is also characterized by flares and remissions steps^{8,11}. Thus, the determination of the aforementioned antibodies in serum samples is relevant not only for diagnosis but also for classification, determination of the state of the disease, as well as for therapeutic evaluation and drug adjustment.^{3,12}

The gold standard technique for ANA determination is *Crithidia luciliae* indirect immunofluorescence (CLIF). In this assay, fluorescence intensity is used for title determination, and, in addition, it can be defined the specific autoantibodies contained in the sample because of

the different staining patterns. Although several commercial kits have been developed with different cellular substrates, these require complex instrumentation and experienced staff, being unsuitable for *point-of-care* applications.^{13–15} Recently, Enzyme Linked Immunosorbent Assay (ELISA) kits have been developed and commercialized. These kits use single or multiple antigen-coated wells (purified or synthetic), such as Ro, La, and dsDNA. However, diversity in antigen and adsorption strategies can affect comparability of the results between labs using kits from different suppliers. Line immuno semi-quantitative assays (variation of immuno-blots) are easy to use and facilitate detection of multiple autoantibodies in one strip. Nevertheless, they generally offer low sensitivity and specificity for certain antibodies.¹⁶

All the assays described above are time-consuming or can only be developed in a centralized laboratory with certificated equipment and technicians, being unable to provide immediate results for flare prediction and drug adjustment therapy. Biosensors emerge as suitable platforms for quick *point-of-care* tests. A biosensor can be described as an analytical device that includes a biological component as sensor, which works in association to a physicochemical transducer.^{17,18} Most biosensors oriented to the detection of autoantibodies employ a dsDNA-coated surface (or other auto-antigen) which is used to capture the autoantibodies in the sample. These can be detected directly (label-free) or indirectly (e.g., with the help of an enzyme-coupled secondary antibody). Some label-free approaches include Surface Plasmon Resonance chips (SPR) or Quartz Crystal Microbalance (QCM) measurements.^{13,19–21} However, electrochemical label-based biosensors are very promising for *point-of-care* tests because of the low costs associated with their automatization and miniaturization.²² In this regard, Konstantinov, Rubin and coworkers have developed an electrochemical sandwich-type immunoassay where nuclear antibodies are detected through current measurements (using redox enzyme-coupled secondary antibodies).^{23–25}

Recently reported electrochemical biosensors as well as commercial kits use a WHO-standardized serum as a reference to measure autoantibody concentrations. Thus, concentrations are reported either in arbitrary units or in title units (maximum serum dilution to obtain a signal

with a suitable signal-to-noise ratio), which are compared against the WHO reference or other previously calibrated positive samples. This is suitable for most clinical applications, but we argue that results expressed in absolute scale (i.e., molarity or grams per liter) are convenient for both basic research and applications where the inclusion of a previously calibrated control is not always possible (e.g., self-monitoring). Furthermore, the WHO-standardized reference serum is not available any longer.²

The previous reasons pushed us to develop an amperometric biosensor capable of detecting α -dsDNA antibodies, which could serve as a diagnostic and disease tracing tool in the near future. We also propose a methodology to obtain absolute α -dsDNA antibody concentrations (in terms of mass per volume), without the need of positive and previously calibrated human sera.

Materials and methods

Reagents and solutions

Lyophilized genomic salmon sperm DNA (“dsDNA”, Sigma-Aldrich, Cat.No. D1626) was employed for ELISA assays and electrode modification. Poly-L-Lysine and 3,3',5,5'-tetramethylbenzidine (TMB, $\geq 98\%$) were purchased from Sigma-Aldrich. Freeze-dried bovine serum albumin (BSA $\geq 96\%$) was obtained from Spectrum Chemical Mfg Corp. (USA) and 1% fresh solutions were made in phosphate buffer saline (“PBS”: 10mM sodium phosphate buffer, 150 mM NaCl, pH = 7.4). Mouse monoclonal anti-dsDNA antibodies (α -dsDNA: sc-58749), normal mouse immunoglobulins (m IgG: sc-2025) and mouse monoclonal anti-human CD9 antibodies (α -CD9: sc-13118) were purchased from Santa Cruz Biotechnology INC. Rabbit HRP-conjugated anti-mouse IgG (α -m-IgG/HRP, ab6728) was purchased from Abcam. Fetal bovine serum (FBS) was supplied by Gibco. Stock DNA concentrations were estimated using a NanoDrop 1000 spectrophotometer (Thermo Scientific). Screen-printed three or four (bi-electrode) electrode strips (work: carbon; counter: carbon, pseudoreference: silver) were

79 supplied by DropSense (Oviedo, Spain). All electrochemical measurements were carried out
80 with a CHI760D workstation (CH Instruments).

81 **ELISA assay**

82 The ELISA assay was carried out as previously described.²⁶ A 96-well ELISA plate
83 (CELLSTAR, Cat.-No.655 180) was pretreated with 100 μ L of 50 μ g/mL poly-L-Lysine
84 solution (in water) for 30 min at room temperature (RT) and washed three times with Tris
85 Borate Saline buffer ("TBS", 10 mM, 150 mM NaCl pH = 7.5). Then, 100 μ L of dsDNA
86 solution (4 μ g/mL in TBS) was incubated for 60 min at RT and washed in the same way as in
87 the previous step. After this, the plate was blocked over-night with 100 μ L of 1% BSA solution
88 at RT, and washed vigorously three times with PBS-0.1% Tween-20 buffer. Then, 100 μ L of
89 PBS dilution containing either α -dsDNA or m IgG (specific and unspecific antibodies
90 respectively) was incubated for 60 min at 37°C and washed with PBS - 0.1% Tween as
91 previously described. 100 μ L of the α -m-IgG/HRP (1/2000 dilution, plus 1% BSA) was
92 dispensed and incubated for 60 min at 37°C. The plate was washed and finally incubated for 30
93 min with 100 μ L of TMB-H₂O₂ solution (2 mM TMB, 1mM H₂O₂ , diluted in 50 mM acetic
94 acid/sodium acetate buffer, pH = 5). The reaction was stopped with 50 μ L of 5M HCl and the
95 absorbance at 450 nm was measured in a microplate reader (Thermo Scientific, Multiskan EX).

96 **Construction of dsDNA-modified electrodes**

97 100 μ L of acetic acid/sodium acetate buffer (200 mM, pH = 5) was placed in order to cover the
98 three or four screen-printed electrodes in each strip, and a potential of +1.7 V was applied for
99 120 s as electrode pretreatment, followed by three washes with the same buffer. A dsDNA
100 solution (0.5 μ g/ μ L in acetic/acetate buffer) was prepared and vortexed for 30s and then 50 μ L
101 were placed on the electrode system. A constant potential of +0.5 V was applied for 300 s for
102 dsDNA immobilization. After washing three times with PBS, 2 μ L of 1 % BSA were deposited
103 (on the working electrode only) and incubated for 30 min at 37 °C in a wet chamber with 100%
104 humidity.

105 The dsDNA immobilization was confirmed by cyclic voltammetry (CV) after successive
106 washing steps. Briefly, 50 μ L of acetic acid buffer were placed on the three electrode system
107 and CV was carried out between -0.2V and +1.0V at a scan rate of 0.05 V/s in order to observe
108 the guanine oxidation signal.

109 **Detection of specific antibodies**

110 Different dilutions of α -dsDNA and m IgG were prepared in PBS. Two microliters of these
111 solutions were placed on the working electrode and incubated for 20 min at 37°C in a wet
112 chamber. For the bi-electrode strips, each antibody was placed in a different working electrode.
113 After this, the electrodes were washed three times with PBS and 2 μ L of α -m-IgG/HRP
114 antibody (1/2000, 1%BSA) was added and incubated under the same experimental conditions.
115 The electrodes were then washed with PBS and 50 μ L of a TMB/H₂O₂ solution was added.
116 Immediately, the working electrode was placed at a constant potential of -0.1V and the TMB
117 reduction current was registered. For optic measurements, only monoelectrodes were employed.
118 After antibody incubations, the TMB/H₂O₂ solution was incubated for 5 min, followed by the
119 addition of 5 μ L of 5M HCl. Two microliters of the mixture were measured at 450 nm using a
120 NanoDrop spectrophotometer.

121 **Performance in serum samples**

122 As an approximation to the analysis of real samples, assays were performed in the bioelectrode
123 strips by spiking α -dsDNA or irrelevant antibodies directly in 1/80 FBS. Here, two different
124 strategies were tested. One strategy (which we called the “two-step” method) consisted in
125 incubating α -dsDNA-containing FBS on the working electrode, performing two wash steps with
126 PBS, and then incubating (20 min at 37°C) the electrodes with 2 μ L of α -m-IgG/HRP antibody
127 (1/2000 dilution, plus 1% BSA) followed by a new washing step and addition of the TMB/H₂O₂
128 solution. In contrast, the “one-step” method consisted in preincubating the α -dsDNA (or
129 irrelevant antibodies) with the α -m-IgG/HRP in FBS. Briefly, 5 μ L of α -dsDNA (in 1/40 FBS)
130 was mixed with 5 μ L of α -m-IgG/HRP (1/1000) and incubated for 5 min at 37°C. Then, 2 μ L of

131 the mixture was placed on the working electrode and the procedure continued the same way as
132 described above. As a consequence, one single incubation with the sample and HRP-conjugated
133 antibodies was needed, avoiding the washing step in between, and reducing assay time
134 approximately two-fold.

135 Results

136 We propose the construction of an amperometric biosensor capable of detecting anti-double
137 stranded DNA antibodies, which offer diagnostic and prognostic value in several auto-immune
138 diseases. This biosensor is based on the specific binding of α -dsDNA antibodies present in a test
139 sample to dsDNA molecules immobilized on the surface of a disposable screen-printed carbon
140 graphite electrode, and the subsequent binding of anti-mouse IgG antibodies conjugated to the
141 electroactive enzyme HRP (conjugated ABs). The electrochemical reduction the oxidized TMB
142 generated by the catalysis of HRP is measured²⁷, what is related to the amount of α -dsDNA
143 antibodies located in the sensor's surface. In an attempt to render this biosensor compatible with
144 automatization, the conjugated ABs were directly introduced in the test sample, greatly
145 simplifying the detection procedure (one-step method, **Scheme 1**).

146 Specificity of the α -dsDNA antibody

147 Specificity of our α -dsDNA antibody was studied by ELISA (**Figure 1**). Wells sensitized with
148 either vortexed or intact dsDNA showed a characteristic binding response when incubated with
149 increasing concentrations of the mouse monoclonal α -dsDNA antibody, with a linear response
150 below 0.07 $\mu\text{g} / \text{mL}$. In contrast, incubation with normal mouse immunoglobulins (m IgG)
151 showed basal absorbance independently of the concentration used, confirming specificity of the
152 assay. Secondly, we assayed the α -dsDNA antibody against genomic DNA, plasmid DNA and a
153 purified PCR product, confirming that it is the dsDNA molecule itself (rather than co-purified
154 nucleosomes present in certain genomic DNA preparations) which is being recognized by the
155 antibody used throughout this study. (**Supplementary Figure 1**).

156 **Electrode modification**

157 Deposition of dsDNA on the working electrode was done at a constant potential as indicated in
 158 Methods. We asked whether that immobilization method would be suitable for maintaining the
 159 dsDNA attached to the electrode surface during the whole procedure. To test this, we subjected
 160 dsDNA-modified BSA-blocked electrodes to a number of washes in PBS, which was equivalent
 161 to the number of washes in our longest assay (three washing cycles, three washes per cycle).
 162 The presence of DNA in the electrodes was then analyzed by measuring the irreversible guanine
 163 oxidation signal²⁸ at +0.83 V by cyclic voltammetry, and comparing this signal with naked
 164 (**Figure 2A**) or BSA-only electrodes (data not shown).

165 **Specificity of the electrochemical biosensor**

166 The electrochemical behavior of TMB on our screen-printed dsDNA-modified carbon
 167 electrodes was studied by cyclic voltammetry (**Supplementary Figure 2**) in order to determine
 168 the working potential where electrochemical TMB oxidation was virtually zero, and also
 169 registering the electrochemical reduction of oxidized TMB. By doing so, we defined -0.1 V as a
 170 suitable applied potential for subsequent constant potential assays.

171 As a proof-of-principle, intensity vs time (I vs t) assays at -0.1 V are shown in **Figure 2B**.
 172 Incubation of dsDNA-modified electrodes with the α -dsDNA monoclonal antibody (followed
 173 by detector ABs and TMB/H₂O₂ solution) showed the expected response²⁷, with a negative (i.e.,
 174 reduction) signal decreasing in absolute value with time, and approaching a concentration-
 175 dependent plateau as predicted by the Cottrell equation.²⁹ Here, total TMB concentration is
 176 constant, but the concentration of oxidized TMB depends on the number of HRP molecules
 177 present at the electrode's surface. In contrast, electrodes incubated with normal mouse IgG
 178 displayed a negligible signal, comparable to electrodes only exposed to the conjugated ABs.
 179 This finding demonstrates that unspecific binding of conjugated ABs to our electrodes is
 180 despicable in the absence of analyte (i.e., α -dsDNA antibodies).

181 **Optical and electrochemical response**

182 Based on the fact that our electrochemical signal depends on the concentration of enzyme-
 183 oxidized TMB, which also absorbs visible light with a maximum at 450 nm after acidification
 184 of the medium, we compared the analytical performance of the sensor by both optical and
 185 electrochemical readouts. Similarly to what was previously observed in ELISA plates (**Figure**
 186 **1**), the absorbance of oxidized TMB was saturated above 0.05 $\mu\text{g} / \text{mL}$ of α -dsDNA antibodies
 187 in carbon/dsDNA/BSA electrodes (**Figure 3A**), with no signs of unspecific binding of
 188 antibodies to the electrode surface. In contrast, the electrochemical response (measured as the
 189 electrical current in I vs t plots at exactly $t = 100$ s) was linear up to approximately 0.5 $\mu\text{g} / \text{mL}$,
 190 showing a 10-fold increase in the dynamic range of the method when compared to absorbance
 191 measurements. It is important to mention that this assays were performed in bi-electrodes,
 192 where both working electrodes were modified simultaneously using the same dsDNA solution,
 193 and incubated with either α -dsDNA antibodies or normal mouse IgGs at exactly the same
 194 concentration. Thus, batch effects (i.e., disparities in electrode fabrication and dsDNA
 195 immobilization) are minimized due to the use of paired data in our assays.

196 By using the standard deviation of all electrodes incubated with mouse IgGs, we determined the
 197 limit of detection (LOD) of our sensor as the background signal (i.e., the average of mouse IgG-
 198 incubated electrodes) plus three standard deviations. We obtained a LOD of 0.1 $\mu\text{g} / \text{mL}$ of α -
 199 dsDNA antibodies, corresponding to a measured current of - 0.1 μA . Currents (cathodic) higher
 200 than that could be taken into account to discriminate samples that contain α -dsDNA antibodies.

201 **Performance in serum samples**

202 Once addressing the sensitivity and specificity of the sensor towards α -dsDNA antibody detection
 203 in buffer, we wondered whether this device would be able to detect these antibodies in a
 204 complex sample mixture such as serum. It is reported that many sensors fail to give a well-
 205 response signal when exposed to real complex matrixes even if their performance indicates the
 206 recognition of specific analytes when using pure laboratory samples.³⁰ To test this, we

performed standard additions of the monoclonal α -dsDNA antibody (or irrelevant antibodies) in 1/80 dilutions of fetal bovine serum. We decided to work in 1/80 serum as this is the dilution used to differentiate positive from negative samples in SLE^{14,15}. Even though we could no longer detect a clear trend in the electrical current as a function of the specific antibody concentration, we did observe a statistically significant ($p < 0.0001$) higher reduction (i.e., negative) current of TMB in electrodes incubated with α -dsDNA-containing FBS vs. mouse IgG-containing FBS (**Figure 4A**). This also depended on the presence of immobilized dsDNA on the surface of the electrodes, as electrodes modified with BSA alone showed background currents even when incubated with α -dsDNA-containing FBS (**Figure 4A, diamonds**). Assuming a cutoff value of 0.1 μ A (which corresponds to the measured current at the LOD), the biosensor was 100% specific (no false positives) and 82% sensitive (3 false negatives out of 17). Similar results were obtained for current measurements at 50 s and for quantization of the electrical charge passed through the electrode during 100s (**Supplementary Figure 3**)

Our next attempt was to reduce assay time and manipulation steps, in order to ease automatization of the sensor in the future. We hypothesized that by adding the conjugated ABs directly into α -dsDNA-containing FBS, we could then incubate both molecules above the electrode surface in a single step, without the need for a washing step in the middle. This method, called “one-step” in opposition to the “two-step” method, reduced the total assay time to 30 min (vs. 60 min in the “two-step”) without compromising specificity (**Figure 4B**), as evident from a comparison of ROC curves for both methods (**Figure 4C**). In contrast, the current separation between positive and negative samples was even higher, with a 100% specificity and 90% sensitivity when using the 0.1 μ A cutoff. To discard that the positives results were not simply a consequence of using monoclonal antibodies instead of normal mouse IgG, we also analyzed other negative samples in which irrelevant monoclonal antibodies (e.g., anti-human CD9) were added to 1/80 FBS at the same concentration as the positive samples (**Figure 4B, triangles**). Overall, these results show that our biosensor is capable of discriminating between serum samples containing α -dsDNA antibodies and those which do not.

234 This is promising towards the future development of electrochemical biosensors for
235 autoimmune disease-based applications.

236

237 Discussion

238 There is a need for rapid, simple and low-cost analytical devices capable of determining the
239 presence and concentration of autoantibodies in blood specimens, to favor disease diagnosis,
240 treatment and monitoring.^{12,31–33} Currently, these assays are carried out in clinical laboratories
241 and demand time, costly equipment and specialized human resources. In contrast,
242 electrochemical biosensors are intrinsically compatible with point-of-care testing^{22,27,34}, and that
243 makes them suitable for decentralized autoantibody determination. However, the number of
244 reports describing electrochemical biosensors for anti-dsDNA autoantibodies (a hallmark of
245 SLE and other autoimmune diseases) is rather scarce (**Table 1**).

246 Some of the important parameters to study when describing new analytical technologies or
247 methods are the sensitivity (often expressed as the limit of detection) and specificity of the
248 assays, as well as the performance of the method in real samples. Previous reports, such as the
249 seminal work performed by Rubin and Konstantinov, have used sandwich immunoassays in
250 fluidic devices to detect anti-dsDNA, anti-nuclear or anti-chromatin autoantibodies with
251 electrochemical biosensors based on a similar electrochemical readout as the used herein.^{23–25}

252 The authors compared the amount of autoantibodies in patient serum samples, and established the
253 performance of their sensor against commercial ELISA kits. However, their output was based
254 on the value of the measured electrochemical current, so establishing comparisons of analytical
255 performances with other methods was difficult, if not impossible. To overcome this problem,
256 we performed calibration curves in artificial samples containing monoclonal anti-dsDNA
257 antibodies, as suggested by Buhl et al. (2009).² We obtained a limit of detection [LOD] of 0.1
258 μg of α -dsDNA antibodies per mL, and used the current in the LOD to define a cut-off in non-

human serum samples were known quantities of specific or irrelevant antibodies were spiked-in. Through this procedure, we obtained a 90% sensitivity and a 100% specificity with the “on-sep” method (i.e., we could label 9 out of 10 positive samples as positive, and 10 out of 10 negative samples as negative). Considering the fact that we used 1/80 dilutions of serum, our real detection limit increases up to 8 µg/mL, which is slightly lower but comparable to previous reports²³

Since reported detection limits are usually based on the title of autoantibodies (i.e., 1 / maximum dilution of a serum sample for which a positive signal is still detected) we wondered whether our detection limit of 8 µg / mL (16 ng total anti-dsDNA antibody, since sample volume is only 2 µL) was clinically relevant. To study this, we performed serial dilutions of FBS spiked-in with known amounts of α-dsDNA antibodies, and looked for the amount which mimicked serial dilutions of a SLE patient serum by ELISA. By doing so, we estimated the α-dsDNA cargo in this patient sample to be precisely 8.8 µg / mL. Thus, the limit of detection of our sensor is in principle compatible with clinical applications. Further optimization will be needed to achieve this goal, as mammalian non-human antibodies and serum were used in this study.

One of the important aspects of our study is the minimization of assay time and manipulation steps achieved with the thus called “one-step” method. If electrochemical biosensors are chosen for their compatibility with point-of-care tests, they should be compatible with automatization in order to avoid the need of specialized technicians. By decreasing the number of manipulation steps (including sample incubation, washes, addition of reactants, among others) we facilitate the implementation of our sensing methodology in future analytical devices. By pre-incubating serum samples with the HRP-conjugated secondary antibodies, we have successfully decreased manipulation steps from 5 (sample incubation, wash, conjugate incubation, wash, TMB /H₂O₂ addition and electrochemical measurement) to 3 (sample incubation, wash, addition of redox mediator and electrochemical measurement). Furthermore, this protocol reduced total assay time from 60 to 30 minutes.

286 Conclusion

287 We provide a simple protocol for the electrochemical sensing of α -dsDNA autoantibodies in
 288 serum samples, with excellent distinction between samples containing or not α -dsDNA
 289 antibodies in concentrations comparable to those present in the sera of autoimmune disease
 290 patients. The total assay time of 30 minutes and the few manipulation steps will aid in the
 291 automatization of this protocol in order to obtain portable sensors for their use outside of
 292 laboratory facilities.

293 Conflicts of Interest

294 There are no conflicts of interest to declare

295 Acknowledgments

296 The authors want to thank Eduardo Méndez (Faculty of Science, Uruguay) for helpful
 297 discussions and Alfonso Cayota (Institut Pasteur de Montevideo) for some of the antibodies
 298 used in this work. JPT is a member of the National System of Researchers (ANII, Uruguay) and
 299 the Program for the Development of Basic Science (PEDECIBA, Uruguay).

References

- 1 A. Lerner, P. Jeremias and T. Matthias, *Int. J. Celiac Dis.*, 2016, **3**, 151–155.
- 2 A. Buhl, S. Page, N. H. H. Heegaard, P. von Landenberg and P. B. Lippa, *Biosens. Bioelectron.*, 2009, **25**, 198–203.
- 3 K. N. Konstantinov, A. Tzamaloukas and R. L. Rubin, *Autoimmun. Highlights*, 2013, **4**, 55–61.
- 4 K. H. Costenbader, S. Gay, M. E. Alarcón-Riquelme, L. Iaccarino and A. Doria, *Autoimmun. Rev.*, 2012, **11**, 604–609.
- 5 E. Cozzani, M. Drosera, G. Gasparini, A. Parodi, E. Cozzani, M. Drosera, G. Gasparini and A. Parodi, *Autoimmune Dis. Autoimmune Dis.*, 2014, **2014**, e321359.
- 6 I. Fattal, N. Shental, D. Mevorach, J. M. Anaya, A. Livneh, P. Langevitz, G. Zandman-Goddard, R. Puzner, M. Lerner, M. Blank, M. E. Hincapié, U. Gafer, Y. Naparstek, Y.

- Shoenfeld, E. Domany and I. R. Cohen, *Immunology*, 2010, **130**, 337–343.
- 7 I. E. A. Hoffman, *Ann. Rheum. Dis.*, 2004, **63**, 1155–1158.
- 8 C. K. Li and D. A. Isenberg, *Medicine (Baltimore)*, 2006, **34**, 445–452.
- 9 S. Ntali and M. Y. Karim, *Transl. Res.*, 2010, **156**, 317–319.
- 10 D. A. Isenberg, C. T. Ravirajan, A. Rahman and J. Kalsi, *Lupus*, 1997, **6**, 290–304.
- 11 M. Petri, *Rheum. Dis. Clin. North Am.*, 2005, **31**, 245–254.
- 12 K. N. Konstantinov and R. L. Rubin, *Autoimmun. Highlights*, 2017, **8**, 17–20.
- 13 F. Fiegel, A. Buhl, H.-P. Jaekel, E. Werle, M. Schmolke, M. Ollert and P. B. Luppa, *Lupus*, 2010, **19**, 957–964.
- 14 O. G. Carballo, F. B. Ingénito, A. A. Ginaca, P. Carabajal, M. A. Costa and J. Balbaryski, 2012, **46**, 3–13.
- 15 A. Dellavance, A. Gabriel Júnior, B. Nuccitelli, B. H. Taliberti, C. A. von Mühlen, C. D. A. Bichara, C. H. R. Dos Santos, C. Bueno, C. M. Yano, C. L. P. Mangueira, D. G. Carvalho, E. Cardoso, E. Bonfá, F. I. E. Araújo, G. G. Rassi, H. M. Mundim, I. Bendet, J. Rego, L. M. E. D. A. Vieira, L. E. C. Andrade, M. O. F. Barbosa, M. Sugiyama, M. B. Santiago, N. Shessarenko, N. A. Da Silva, P. L. C. Francescantonio, R. Jarach, R. Suda, R. A. Levy, S. O. Sampaio, S. P. F. Neves, W. D. M. Cruvinel, W. S. Dos Santos and Y. K. D. M. Nóbrega, *Rev. Bras. Reumatol.*, 2009, **49**, 89–98.
- 16 N. J. Olsen, M. Y. Choi and M. J. Fritzler, *Arthritis Res. Ther.*, 2017, **19**, 172.
- 17 M. Mascini and S. Tombelli, *Biomarkers*, 2008, **13**, 637–657.
- 18 G. S. Turner, A.P.F., Karube, I. and Wilson, *Biosensors: Fundamentals and Applications*, Oxford University Press, Oxford., 1987.
- 19 A. Buhl, J. H. Metzger, N. H. H. Heegaard, P. Von Landenberg, M. Fleck and P. B. Luppa, *Clin. Chem.*, 2007, **53**, 334–341.
- 20 N. M. do Nascimento, A. Juste-Dolz, E. Grau-García, J. A. Román-Ivorra, R. Puchades, A. Maquieira, S. Morais and D. Gimenez-Romero, *Biosens. Bioelectron.*, 2017, **90**, 166–173.
- 21 R. F. Fakhrullin, V. G. Vinter, A. I. Zamaleeva, M. V. Matveeva, R. A. Kourbanov, B. K. Temesgen, D. G. Ishmuchametova, Z. I. Abramova, O. A. Konovalova and M. K. Salakhov, *Anal. Bioanal. Chem.*, 2007, **388**, 367–375.
- 22 A. P. F. Turner, *Chem. Soc. Rev.*, 2013, **42**, 3184.
- 23 R. L. Rubin, D. Wall and K. N. Konstantinov, *Biosens. Bioelectron.*, 2014, **51**, 177–183.
- 24 R. L. Rubin and K. N. Konstantinov, *Biosens. Bioelectron.*, 2016, **83**, 306–311.
- 25 K. N. Konstantinov, R. A. Sitdikov, G. P. Lopez, P. Atanassov and R. L. Rubin, *Biosens. Bioelectron.*, 2009, **24**, 1949–1954.
- 26 A. Debesa Padilla and O. Hernández Betancourt, *Rev. Cuba. Investig. Biomédicas*, 2012, **31**, 467–479.
- 27 X. Doldán, P. Fagúndez, A. Cayota, J. Laíz and J. P. Tosar, *Anal. Chem.*, 2016, **88**, 10466–10473.
- 28 J. P. Tosar, J. L. Holmes, S. D. Collyer, F. Davis, J. Laíz and S. P. J. Higson, *Biosens. Bioelectron.*, 2013, **41**, 294–301.

- 29 F. G. Cottrell, *Z. Phys. Chem*, 1903, **42**, 385.
- 30 J. P. Tosar, G. Brañas and J. Laíz, *Biosens. Bioelectron.*, 2010, **26**, 1205–1217.
- 31 M. Sher, R. Zhuang, U. Demirci, W. Asghar, F. Atlantic, B. Raton, B. Raton, E. Detection, P. Alto and B. Raton, *Expert Rev Mol Diagn*, 2017, **17**, 351–366.
- 32 M. Thaler, A. Buhl, H. Welter, A. Schreiegg, M. Kehrel, B. Alber, J. Metzger and P. B. Lippa, 2009, 1417–1429.
- 33 X. Zhang, A. Zambrano and Z. L. Yikun, *Arch. Immunol. Ther. Exp. (Warsz.)*, 2017, **65**, 111–121.
- 34 J. P. Tosar, K. Keel and J. Laíz, *Biosens. Bioelectron.*, 2009, **24**, 3036–3042.
- 35 Z. Li, F. Li, Y. Xing, Z. Liu, M. You, Y. Li, T. Wen, Z. Qu, X. Ling Li and F. Xu, *Biosens. Bioelectron.*, 2017, **98**, 478–485.
- 36 R. Nosrati, B. Golichenari, A. Nezami, S. M. Taghdisi, B. Karimi, M. Ramezani, K. Abnous and S. A. M. Shaegh, *TrAC - Trends Anal. Chem.*, 2017, **97**, 428–444.
- 37 L. A. Fraser, A. B. Kinghorn, R. M. Dirkzwager, S. Liang, Y. W. Cheung, B. Lim, S. C. C. Shiu, M. S. L. Tang, D. Andrew, J. Manitta, J. S. Richards and J. A. Tanner, *Biosens. Bioelectron.*, 2018, **100**, 591–596.
- 38 K. Papp, E. Holczer, C. Kecse-Nagy, Z. Szittner, V. Lóránd, P. Rovero, J. Prechl and P. Fürjes, *Sensors Actuators, B Chem.*, 2017, **238**, 1092–1097.
- 39 M. Fritzler, *Lupus*, 2006, **15**, 422–427.

300 Figure Legends

301 **Scheme 1. Detection strategy.** Positive or negative serum samples (containing 1/80 fetal
302 bovine serum plus either murine monoclonal anti-dsDNA [red] or irrelevant [green] antibodies)
303 were incubated with dsDNA-modified carbon electrodes, washed, and later incubated with anti-
304 mouse IgG antibodies conjugated to HRP enzyme [blue] (A). In a more time-efficient and
305 automatization-compatible strategy, conjugated antibodies were mixed with the serum samples
306 before incubation (one-step, B).

307 **Figure 1. Specificity of α -dsDNA antibody by enzyme-linked immunosorbent assay.** Plates
308 were sensitized with vortexed (squares) or intact (circles) salmon sperm DNA and incubated
309 with different concentrations of α -dsDNA antibody (black) or mouse IgGs as a control (white).

310 **Figure 2. Electrode modification with dsDNA and electrochemical sensing of α -dsDNA**
311 **antibodies.** A) cyclic voltammograms showing guanine oxidation (arrow) in dsDNA-modified
312 electrodes (solid line) vs buffer-treated (dashed line) screen-printed carbon electrodes. B)
313 Intensity vs time curves for TMB reduction on the electrode surface at – 0.1 V. dsDNA-
314 modified BSA-blocked electrodes were incubated with α -dsDNA antibodies at two different
315 concentrations (solid lines), normal mouse IgG at 2.5 μ g / mL (thick dashed line), or buffer (thin

316 dashed line), and then incubated with α -mouse IgG/HRP conjugates, followed by addition of a
317 TMB/H₂O₂ solution.

318 **Figure 3. Optical and electrochemical response of the sensor.** A) Absorbance changes as a
319 function of the concentration of m α -dsDNA (black circles) or mouse IgGs (open circles). B)
320 Reduction current of TMB at 100s as function of the concentration of α -dsDNA (black circles)
321 or mouse IgGs (open circles). LOD (limit of detection) was determined as the background
322 signal plus three standard deviations. For visualization purposes, the current axis direction was
323 inverted. Error bars correspond to the standard error of the mean of two independent replicates.
324 Bi-electrodes containing specific and irrelevant antibodies at the same concentration were
325 assayed in parallel.

326 **Figure 4. “One-step” vs “two-step” method.** Reduction current recorder at 100s after
327 incubation with serum samples containing either relevant or irrelevant antibodies at the same
328 concentration with the “two-step” (A) or “one-step” (B) method. To reduce batch effects,
329 specific (black circles) and irrelevant (mouse IgG: open circles; monoclonal α -human CD9,
330 open triangles) antibody-containing samples were incubated in parallel in bi-electrode strips.
331 Diamonds correspond to carbon electrodes not modified with dsDNA (negative controls). Error
332 bars correspond to the standard error of the mean. Student *t* test (two-tailed) was carried out to
333 test statistically significance in the difference between positives and negatives. The current
334 corresponding to the detection limit of the method was used as cut-off in order to establish assay
335 specificity and sensitivity. Alternatively, a mobile cut-off was used in order to obtain ROC
336 (receiving operating characteristic) curves for both methods (C).

Table 1. Assay time and limit of detection of different biosensors for analysis of autoantibodies.

Biosensor/Transductor	Target	Time assay (min)	Sample amount* (μ L)	LOD	Ref
QCM	α -TRIM21(Ro52)/ α -TROVE2(Ro60)	> 60	1000	NR	20
	α -dsDNA	NR	2000	NR	21
SPR	α -dsDNA	15	45	NR	19;13
Electrochemical	α -chromatin	30	200	NR	25
	ANA	30	200	NR	24
	α -dsDNA	30	200	10 μ g/mL	23
	α -dsDNA (two-step)	60	2	8 μ g/mL	This work
	α -dsDNA (one-step)	30			

QCM: Quartz Crystal Microbalance. SPR: Surface Plasmon Resonance

ANA: Total Antinuclear Antibody.

NR: not reported.

*Diluted serum samples

A **B**

A **B** **C**

dsDNA

BSA

irrelevant ABs

m α-dsDNA

α-mIgG/HRP

A: two-step method

B: one-step method

50% REDUCTION:

- ASSAY TIME
- MANIPULATION STEPS